ImmunoPrecise Antibodies (NASDAQ:IPA - Get Free Report) is projected to release its Q4 2025 earnings data before the market opens on Tuesday, July 29th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $7.89 million for the quarter.
ImmunoPrecise Antibodies Stock Performance
Shares of NASDAQ IPA traded up $0.12 during mid-day trading on Wednesday, hitting $1.82. The company had a trading volume of 929,076 shares, compared to its average volume of 2,629,091. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.32 and a quick ratio of 2.11. The business's 50-day simple moving average is $0.95 and its 200-day simple moving average is $0.62. ImmunoPrecise Antibodies has a 12 month low of $0.27 and a 12 month high of $2.32. The firm has a market cap of $83.29 million, a P/E ratio of -1.57 and a beta of 0.44.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on the stock. Wall Street Zen raised shares of ImmunoPrecise Antibodies to a "sell" rating in a report on Saturday, May 24th. Benchmark restated a "speculative buy" rating and set a $3.00 target price on shares of ImmunoPrecise Antibodies in a research report on Tuesday, April 1st. Finally, HC Wainwright restated a "buy" rating and set a $5.00 target price on shares of ImmunoPrecise Antibodies in a research report on Friday, April 11th.
View Our Latest Stock Analysis on ImmunoPrecise Antibodies
About ImmunoPrecise Antibodies
(
Get Free Report)
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.
Read More

Before you consider ImmunoPrecise Antibodies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunoPrecise Antibodies wasn't on the list.
While ImmunoPrecise Antibodies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.